Shuyan Meng

First-line continual EGFR-TKI plus local ablative therapy demonstrated survival benefit in EGFR-mutant NSCLC patients with oligoprogressive disease

Qinghua Xu, Hui Liu, Shuyan Meng et al. · Journal of Cancer · 2019 · 62 citations · Full text

Enhanced antitumor effect of novel dual-targeted paclitaxel liposomes

Shuyan Meng, Bo Su, Wěi Li et al. · Nanotechnology · 2010 · 61 citations

Novel Dual-targeted Peptide, Drug Targeting, Engineering +15

Integrin-targeted paclitaxel nanoliposomes for tumor therapy

Shuyan Meng, Bo Su, Wěi Li et al. · Medical Oncology · 2010 · 52 citations

Nanomedicine, Drug Targeting, Integrin-targeted Paclitaxel Nanoliposomes +3

A Phase 1b Study of Ivonescimab, a Programmed Cell Death Protein-1 and Vascular Endothelial Growth Factor Bispecific Antibody, as First- or Second-Line Therapy for Advanced or Metastatic Immunotherapy-Naive NSCLC

Lei Wang, Yongzhong Luo, Shengxiang Ren et al. · Journal of Thoracic Oncology · 2023 · 50 citations · Full text

Fabrication and characterization of chitosan coated braided PLLA wire using aligned electrospun fibers

Wen Hu, Zheng‐Ming Huang, Shuyan Meng et al. · Journal of Materials Science Materials in Medicine · 2009 · 42 citations

Materials Science, Nanofiber, Plla Wire +2